Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
126 hedge funds and large institutions have $447M invested in Terns Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 45 increasing their positions, 24 reducing their positions, and 25 closing their positions.
359% more call options, than puts
Call options by funds: $3.72M | Put options by funds: $809K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
88% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 24
60% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 25
13% more funds holding
Funds holding: 112 → 126 (+14)
8% more capital invested
Capital invested by funds: $415M → $447M (+$31.8M)
3.58% more ownership
Funds ownership: 97.82% → 101.4% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$30M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$6.5M |
| 3 |
SCM
Superstring Capital Management
New York
|
+$5.79M |
| 4 |
BlackRock
New York
|
+$4.88M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$4.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$13.9M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$13.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.12M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$8.95M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$7.82M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$12 | +2 | New |
|
TERN Hedge Fund Activity: Q2 2024 in Review
126 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q2 2024, worth a combined $447M — up 7.7% from $415M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new TERN positions and 25 closed out — a net gain of 15 holders — while 45 added to existing stakes and 24 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $30M. The largest seller was Millennium Management, cutting an estimated $13.9M.
- 126 institutional investors held Terns Pharmaceuticals (TERN) as of Q2 2024, up from 112 in Q1 2024.
- Funds reported $447M of Terns Pharmaceuticals stock for Q2 2024, up 7.7% quarter-over-quarter.
- 40 funds opened new Terns Pharmaceuticals positions in Q2 2024 and 25 closed out, a net change of +15 holders.
- The largest Terns Pharmaceuticals buyer in Q2 2024 was Soleus Capital Management, an estimated $30M added.
- The largest Terns Pharmaceuticals seller in Q2 2024 was Millennium Management, an estimated $13.9M sold.
Based on aggregated 13F filings for Q2 2024.